Patents by Inventor Markus Weigandt

Markus Weigandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210100903
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 8, 2021
    Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
  • Publication number: 20210085611
    Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-tnorpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 28, 2018
    Publication date: March 25, 2021
    Applicant: Merck Patent GmbH
    Inventors: Simon GEISSLER, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
  • Publication number: 20200237733
    Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Simon GEISSLER, Stefan SCHILLER, Meike HARMS, Holger KUBAS, Markus WEIGANDT, Michael LANGE
  • Patent number: 10561622
    Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: February 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Andrea Hanefeld, Markus Weigandt, Stefan Schiller, Marc Schneider, Michael C. Lehr
  • Patent number: 10561733
    Abstract: The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: February 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Markus Weigandt, Senta Voss, Tobias Miller, Achim Goepferich
  • Patent number: 10369217
    Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 6, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Andrea Hanefeld, Markus Weigandt, Michael Wolf, Percy Knolle, Matthias Schroeder, Regina Scherliess, Peter Walden, Andrea Diedrich, Hartwig Steckel, Renato Brito Baleeiro
  • Publication number: 20180369377
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 27, 2018
    Applicants: MERCK PATENT GmbH, PFIZER INC.
    Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
  • Patent number: 10111952
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 30, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Publication number: 20180071386
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Patent number: 9808521
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 7, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Publication number: 20170312229
    Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).
    Type: Application
    Filed: October 15, 2015
    Publication date: November 2, 2017
    Applicant: Merck Patent GmbH
    Inventors: Andrea HANEFELD, Markus WEIGANDT, Stefan SCHILLER, Marc SCHNEIDER, Michael C. LEHR
  • Publication number: 20170143822
    Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.
    Type: Application
    Filed: May 12, 2015
    Publication date: May 25, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Andrea HANEFELD, Markus WEIGANDT, Michael WOLF, Percy KNOLLE, Matthias SCHROEDER, Regina SCHERLIESS, Peter WALDEN, Andrea DIEDRICH, Hartwig STECKEL, Renato Brito BALEEIRO
  • Publication number: 20160303228
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Application
    Filed: June 30, 2016
    Publication date: October 20, 2016
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Publication number: 20160279213
    Abstract: The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules.
    Type: Application
    Filed: December 16, 2014
    Publication date: September 29, 2016
    Inventors: Simon Geissler, Patrizia Boniforte, Joerg Plaschke, Markus Weigandt, Stefan Jaekel, Roland Kellner, Thomas Rysiok, Dirk Mueller-Pompalla, Kenneth Hance
  • Patent number: 9433673
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: September 6, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Publication number: 20150224189
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Application
    Filed: February 2, 2015
    Publication date: August 13, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Patent number: 8980324
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: March 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Publication number: 20150051181
    Abstract: The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Senta Voss, Tobias Miller, Achim Goepferich
  • Publication number: 20110123620
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.
    Type: Application
    Filed: July 13, 2009
    Publication date: May 26, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig